{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260602060341/en/Agilent-Receives-FDA-Approval-for-Expanded-Use-of-PD-L1-IHC-22C3-pharmDx-on-Dako-Omnis-in-Esophageal-Squamous-Cell-Carcinoma-Triple-Negative-Breast-Cancer-Cervical-Cancer-and-Gastric-or-Gastroesophageal-Junction-Adenocarcinoma", "message": "News view counter 774999 successfully enlarged"}